Please assess the completion status of the following clinical trial:

Trial Title: Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented metastatic renal cell cancer with a component of clear cell histology.~* Evidence of measurable disease.~* Patients with mRCC must have received no prior systemic first-line therapy or must have progressive disease per RECIST (version 1.0) after one prior systemic first line regimen for metastatic disease containing sunitinib, cytokine(s), or both.~Exclusion Criteria:~* Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy.~* Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).